SCHEMBL6899728

SCHEMBL6899728

O=S(=O)(C=C1CN(C(c2ccc(Cl)cc2)c2cccs2)C1)Cc1cc(F)cc(F)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.35
ALOX15 P16050 1/20 0.33
ALDH1A1 P00352 2/20 0.32
TSHR P16473 2/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
DRD3 P35462 2/20 0.32
DRD2 P14416 1/20 0.32
LMNA P02545 4/20 0.32
POLB P06746 2/20 0.32
SLC6A3 Q01959 2/20 0.31
KDM4E B2RXH2 1/20 0.31
OPRM1 P35372 1/20 0.31
OPRD1 P41143 1/20 0.31
OPRK1 P41145 1/20 0.31
OPRL1 P41146 1/20 0.31
MAPT P10636 3/20 0.31
TP53 P04637 2/20 0.31
CHRM2 P08172 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6647473 1.00 TDP1 (0.35) TDP1ALOX15ALDH1A1TSHRHTT
SCHEMBL6646348 1.00 TDP1 (0.35) TDP1ALOX15ALDH1A1TSHRHTT
SCHEMBL3294245 0.90 ALDH1A1 (0.34) ALDH1A1TSHRHTTSMN1; SMN2NPSR1
SCHEMBL4029679 0.89 GPX4 (0.35) ALOX15SMN1; SMN2DRD3DRD2LMNA
SCHEMBL3297618 0.84 GPX4 (0.34) SLC6A9CYP2D6
SCHEMBL3298446 0.84 GPX4 (0.34) ALDH1A1NPSR1LMNAOPRK1KCNH2
SCHEMBL3299155 0.84 GPX4 (0.34) ALDH1A1NPSR1LMNAOPRK1KCNH2
SCHEMBL3295171 0.83 HSD17B10 (0.34) SLC6A9CYP2D6
SCHEMBL7646797 0.81 CNR1 (0.39) CNR1
SCHEMBL3304386 0.80 OPRM1 (0.31) ALOX15SMN1; SMN2DRD3DRD2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423146-A1 COMPOSITION FOR TREATING PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT ACTIVATING DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN Aventis Pharma S.A. (FR) 2004-06-02 EP disclosed
WO-2003018060-A1 COMPOSITION FOR TREATING PARKINSON'S DISEASE CONTAINING A CB1 RECEPTOR ANTAGONIST AND A PRODUCT ACTIVATING DOPAMINERGIC NEUROTRANSMISSION IN THE BRAIN AVENTIS PHARMA S.A. (FR) 2003-03-06 WO disclosed